I think it shows a management trying to keep its shareholders informed and convey strongly that the B license deal is hinged on that FDA EOP2 meeting. We knew this already but when capital is so scarce and expensive we need such assurances, so it's good to see them.
But nothing more momentous than that. What's your take?
Market Data 
Markets 
AI
